The Quad Investors Network Launches with Advisory Board, Expert Groups
The Quad Investors Network formally launched today in parallel with the Quad Leaders meeting in Hiroshima, Japan. The Network is an independent forum of public, private, and philanthropic stakeholders from the four Quad nations, created to foster cooperation, collaboration, and co-investment into critical technologies and supply chain resilience to develop innovative solutions to the greatest economic and security challenges in the Indo-Pacific region. Membership in the network is by invitation only.
Governments participating in the security dialogue, a strategic endeavor between Australia, India, Japan, and the United States, also jointly welcomed the formation of the board and the network’s continued efforts to expand capital and partnership opportunities in critical and emerging technologies across the Quad.
“Critical and emerging technologies will profoundly shape our future. By seeking to accelerate the development and manufacturing of these technologies, from semiconductors to quantum to clean energy, the Quad Investors Network demonstrates the tremendous potential of the Quad nations to mobilize world-class talent and investment to foster a more prosperous, resilient, and innovative Indo-Pacific,” said Jake Sullivan, U.S. National Security Advisor.
As part of the launch, the Quad Investors Network announced the formation of an Advisory Board, composed of world-class business, investment, and thought leaders from the four Quad nations. The Advisory Board includes former Telstra CEO Andy Penn AO; former Australian Ambassador to the United States Arthur Sinodinos AO; Founder and CEO of Breyer Capital Jim Breyer; former Bell Labs President Jeong Kim; Chairman Emeritus of JSR Corporation Koshiba Mitsunobu; and Japan Business Federation Managing Director Hara Ichiro.
“The Quad Investors Network serves as an important, exciting forum for executives, investors, and technologists to collaborate and generate greater co-investment in critical and emerging technologies. These technologies will only grow in importance in the future, and I am honored to be a member of the network’s Advisory Board,” said former Telstra CEO Andy Penn.
The Quad Investors Network also established five expert working groups focused on artificial intelligence, semiconductors, clean energy and critical minerals, mobile networks, and quantum information sciences.
Entrepreneur and investor Karl Mehta will serve as the inaugural Chairman of the Quad Investors Network. Mehta is a serial entrepreneur, author, investor, engineer, and civil servant with more than 30 years of experience in founding, building, and funding technology companies in the U.S. and international markets.
“I am honored to lead, and be a part, of such an august group of individuals and organizations which have come together to work on some of the most pressing critical technology issues facing the Quad,” said Mehta. “I look forward to making further progress and contributing to the economic and national security of the four Quad nations through our efforts.”
Full List of the Quad Investors Network Advisory Board:
- Thomas Bell, CEO of Leidos
- Jim Breyer, Founder and CEO of Breyer Capital
- Kris Gopalakrishnan, Chairman of Axilor Ventures
- Hara Ichiro, Managing Director of Japan Business Federation
- Hon. Joe Hockey, Founding Partner and President of Bondi Partners
- Ashok Jacob, Executive Chairman and Portfolio Manager for Ellerston Capital
- Lydia Jett, Managing Partner at Softbank Investment Advisers
- Jeong Kim, Chairman of Kiswe Mobile Inc.
- Koshiba Mitsunobu, Chairman Emeritus of JSR Corporation
- Arun Kumar, Managing Partner of Celesta Capital
- Paul Kwan, General Partner at General Catalyst
- Nakahama Fumitaka, Managing Corporate Executive and Group Head of Global Corporate and Investment Banking Business at MUFG
- Jeff Nuechterlein, Managing Partner of Nue Capital LLC
- Andy Penn AO, Former CEO of Telstra
- Bec Shrimpton, Defence Strategy and National Security Director at the Australian Strategic Policy Institute
- Hon. Arthur Sinodinos AO, Former Australian Ambassador to the United States
- Hon. Sugiyama Shinsuke, Former Japanese Ambassador to the United States
- Yanase Tadao, Senior Executive Vice President at Nippon Telegraph and Telephone Corporation
- Ankur Verma, Senior Vice President at Tata Sons
About The Quad Investors Network: The Quad Investors Network (“The Network”) was formed to develop innovative solutions to the greatest economic and security challenges facing the Quad nations in the Indo-Pacific region through joint research, co-investments, and strategic partnerships. The network will be an independent, membership forum composed of leading industry, government, capital market, and academic organizations from the Quad nations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230520005025/en/
Contact information
Alex El-Fakir
201-328-2930
info@quadinvestorsnetwork.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
